September 25, 2022

Medical Trend

Medical News and Medical Resources

Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines

Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines



 

Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines


On May 9, Johnson & Johnson announced that it had terminated its partnership and licensing agreement with Bavarian Nordic.

The main content of the agreement is to use Bavarian Nordic’s MVA-BN technology to develop potential vaccines against hepatitis B virus and human papilloma virus. Currently, J&J has not used the technology to develop a hepatitis B vaccine.

 

Johnson & Johnson ends partnership with Bavarian Nordic on hepatitis B and HPV vaccines

 

 

For hepatitis B, Johnson & Johnson will continue to prioritize the use of its technology platform to develop related therapeutic drugs. Because hepatitis B remains a serious health problem, about 296 million people worldwide are affected by the disease, and nearly 900,000 people die from it every year.

 

For human papillomavirus, J&J does not intend to focus its research on its therapeutic vaccine because a preventive vaccine is already widely used.

 

However, J&J’s collaboration with the company on HIV and Ebola is still ongoing.

 

(source:internet, reference only)


Disclaimer of medicaltrend.org